BILI

Put Contract Overview: The $25.00 put contract for BILI has a bid of 89 cents, allowing investors to buy shares at a cost basis of $24.11, which is a 3% discount to the current price of $25.87. There is a 61% chance the contract may expire worthless, potentially yielding a 3.56% return on cash commitment.

Call Contract Overview: The $28.00 call contract has a bid of 77 cents, and if shares are purchased at $25.87 and the call is sold, it could yield an 11.21% return if the stock is called away by January 2026. There is a 55% chance this contract may also expire worthless, providing a potential 2.98% additional return.

Volatility Insights: The implied volatility for the put contract is 70% and for the call contract is 72%, while the actual trailing twelve-month volatility is calculated at 59%, indicating market expectations for price fluctuations.

YieldBoost Concept: The article discusses the concept of YieldBoost, which refers to the additional returns investors can earn from options contracts, highlighting the potential annualized returns of 25.99% for the put and 21.73% for the covered call if they expire worthless.

Analyst Recommendation: B of A Securities has maintained a Buy recommendation for Bilibili Inc. - Depositary Receipt (NasdaqGS:BILI) as of November 28, 2025, with an average one-year price target of $30.31/share, indicating a potential upside of 13.85% from its current price of $26.62/share.

Revenue and EPS Projections: The projected annual revenue for Bilibili Inc. is expected to reach 36,712MM, reflecting a 23.36% increase, while the projected annual non-GAAP EPS is -4.60.

Fund Sentiment: There are currently 203 funds reporting positions in Bilibili, with a slight decrease in ownership by 0.98% over the last quarter. The average portfolio weight for these funds has increased by 22.33% to 0.21%.

Shareholder Activity: Notable increases in shareholdings were reported by UBS Group (42.23% increase), Susquehanna International Group (59.13% increase), and Arrowstreet Capital (14.44% increase), while Jane Street Group and Yiheng Capital Management reported decreases in their allocations.

Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets for various companies, with notable changes including Ascendiant Capital lowering 60 Degrees Pharmaceuticals' target from $3 to $2.8 while maintaining a Buy rating.

Price Target Increases: UBS raised the price target for Five Below from $184 to $204, and Telsey Advisory Group increased Macy's target from $17 to $22, both maintaining Buy or Market Perform ratings.

Price Target Decreases: JP Morgan cut the price target for Cabot Corp from $75 to $54 and Orion SA from $9 to $5, both maintaining Underweight ratings.

Mixed Ratings: Barclays adjusted targets for several companies, including raising Abercrombie & Fitch's target from $84 to $94 while maintaining an Equal-Weight rating, and cutting Dick’s Sporting Goods' target from $246 to $242 but keeping an Overweight rating.